swapping from semaglutide to tirzepatide Switching dosage chart Switch from Semaglutide to Tirzepatide

Retatrutide's novel triple-agonist mechanism could trigger an advisory committee a first-in-class mechanism warrants external expert input

Given the results, the addition of tirzepatide to basal insulin in patients with inadequately controlled T2DM resulted in a substantial lowering of HbA1c (Rosenstock et al

Jastreboff, et al., 'Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA', Lancet , vol

2r) and similar glucose uptake into eWAT, skeletal muscle, liver and heart (Fig

Wegovy is excluded almost everywhere

While semaglutide does not require dose adjustment for mild to moderate renal impairment, experience in patients with severe renal impairment is limited